Clinical Trials Logo

HER2-expressing Cancers clinical trials

View clinical trials related to HER2-expressing Cancers.

Filter by:
  • None
  • Page 1

NCT ID: NCT05027139 Recruiting - Clinical trials for HER2-expressing Cancers

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Start date: September 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced [inoperable] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.

NCT ID: NCT03821233 Active, not recruiting - Clinical trials for HER2-expressing Cancers

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Start date: April 15, 2019
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

NCT ID: NCT02892123 Active, not recruiting - Clinical trials for HER2-expressing Cancers

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Start date: September 30, 2016
Phase: Phase 1
Study type: Interventional

This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).